At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border ...

Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...

The concerns of October 10, 1857, sound remarkably familiar today.

The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...

There is still a lot to be learned about the complicated relationship between blood pressure (BP) and glaucoma, and it has taken a while to amass the body of knowledge available today. Some of the ...

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal ...

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about ...

Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, ...

Elizabeth A. Davis MD, FACS | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology ...

Steve Swalgen is national director of lab business, Santinelli International, Hauppauge, NY. Swalgen also is an advisory board member of the Optical Laboratory Association (OLA) and has developed and ...

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day. Cataract remains a leading cause of vision impairment and blindness worldwide.